Morgan Stanley
TRDA icon

Morgan Stanley’s Entrada Therapeutics TRDA Stock Holding History

Morgan Stanley’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Buy
191,650
+15,524
+9% +$149K ﹤0.01% 5047
2026
Q1 		$2.22M Sell
176,126
-84,125
-32% -$964K ﹤0.01% 4701
2025
Q4 		$2.68M Sell
260,251
-86,505
-25% -$729K ﹤0.01% 4607
2025
Q3 		$2.01M Buy
346,756
+183,659
+113% +$1.07M ﹤0.01% 4779
2025
Q2 		$1.1M Buy
163,097
+89,436
+121% +$720K ﹤0.01% 5049
2025
Q1 		$666K Sell
73,661
-8,212
-10% -$102K ﹤0.01% 5198
2024
Q4 		$1.42M Sell
81,873
-11,393
-12% -$206K ﹤0.01% 4917
2024
Q3 		$1.49M Buy
93,266
+44,215
+90% +$697K ﹤0.01% 4818
2024
Q2 		$699K Sell
49,051
-58,511
-54% -$832K ﹤0.01% 5145
2024
Q1 		$1.52M Buy
107,562
+58,258
+118% +$824K ﹤0.01% 4724
2023
Q4 		$744K Buy
49,304
+28,358
+135% +$420K ﹤0.01% 5107
2023
Q3 		$331K Sell
20,946
-8,957
-30% -$141K ﹤0.01% 5342
2023
Q2 		$453K Sell
29,903
-11,865
-28% -$163K ﹤0.01% 5264
2023
Q1 		$606K Buy
41,768
+16,882
+68% +$225K ﹤0.01% 5142
2022
Q4 		$336K Buy
24,886
+14,356
+136% +$252K ﹤0.01% 5435
2022
Q3 		$166K Sell
10,530
-10,655
-50% -$135K ﹤0.01% 5818
2022
Q2 		$258K Buy
21,185
+12,824
+153% +$97.3K ﹤0.01% 5768
2022
Q1 		$78K Buy
8,361
+4,199
+101% +$45K ﹤0.01% 6470
2021
Q4 		$71K Buy
+4,162
New +$101K ﹤0.01% 6632

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Morgan Stanley's TRDA Position: Q2 2026 in Review

Morgan Stanley increased its Entrada Therapeutics (TRDA) stake by 8.8% in Q2 2026, buying an estimated $149K and bringing the position to 191,650 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #5047.

Morgan Stanley first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.68M in Q4 2025. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Morgan Stanley held 191,650 shares of Entrada Therapeutics worth $1.41M as of Q2 2026.
  • Morgan Stanley bought 15,524 Entrada Therapeutics shares in Q2 2026, an estimated $149K.
  • Entrada Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5047 holding.
  • Morgan Stanley first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Morgan Stanley's Entrada Therapeutics position peaked at $2.68M in Q4 2025.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.